Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.51 |
| ▸ | PPARA | Q07869 | 8/20 | 0.51 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738511 | 0.85 | KDM4E (0.60) | PPARGPPARAKDM4EHRH3HPGD | |
| SCHEMBL1981068 | 0.81 | PPARG (0.54) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL3578037 | 0.81 | PPARG (0.51) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL3583269 | 0.78 | PPARA (0.52) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL5023940 | 0.77 | TARBP2 (0.50) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL5093853 | 0.77 | TARBP2 (0.54) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL3996100 | 0.77 | TARBP2 (0.50) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL14431360 | 0.77 | TARBP2 (0.50) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL4830096 | 0.77 | TARBP2 (0.50) | PPARGPPARATARBP2KDM4EHRH3 | |
| SCHEMBL3586207 | 0.76 | PPARG (0.47) | PPARGPPARATARBP2KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1989115-B | Oxazole derivatives as histamine H3 receptor drugs and preparation and pharmaceutical use thereof | LILLY CO ELI | 2012-03-21 | — | — | CN | disclosed |
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1786790-B1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| EP-1786790-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006019833-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | PPARG 1272/4885PPARA 1387/4885TARBP2 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.